Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.58 |
| ▸ | RAB9A | P51151 | 4/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | CFTR | P13569 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.47 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6669684 | 0.87 | NPC1 (0.60) | NPC1RAB9AMAPTCFTRL3MBTL1 | |
| SCHEMBL6800635 | 0.85 | NPC1 (0.58) | NPC1RAB9AMAPTCFTRLMNA | |
| SCHEMBL31070252 | 0.78 | NPC1 (0.67) | NPC1RAB9AMAPTCFTRLMNA | |
| SCHEMBL31393753 | 0.77 | CHRNB2 (0.78) | NPC1RAB9AMAPTL3MBTL1LMNA | |
| SCHEMBL6793651 | 0.76 | NPC1 (0.63) | NPC1RAB9AMAPTL3MBTL1LMNA | |
| SCHEMBL7085439 | 0.76 | NPC1 (0.53) | NPC1RAB9AMAPT | |
| SCHEMBL6664034 | 0.76 | NPC1 (0.60) | NPC1RAB9AMAPTCFTRMAOA | |
| SCHEMBL31156451 | 0.74 | NPC1 (1.00) | NPC1RAB9AMAPTCFTRMAOA | |
| SCHEMBL4761937 | 0.74 | NPC1 (1.00) | NPC1RAB9AMAPTCFTRMAOA | |
| Hydrochloric Acid SCHEMBL6801121 | 0.74 | CHRNB2 (0.59) | NPC1RAB9AMAPTL3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040157866-A1 | Amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157866-A1 | Amide compounds | APOB, NR1H2, NR1H3 | NPC1 40/4885RAB9A 4004/4885MAPT 4047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.